A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Sirolimus (Primary) ; Cancer vaccine NY-ESO-1; MIS 416
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 24 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 15 Dec 2017.
- 20 Oct 2017 Planned initiation date changed from 15 Oct 2017 to 15 Nov 2017.
- 25 Sep 2017 Planned initiation date changed from 15 Sep 2017 to 15 Oct 2017.